DZD9008
≥98%
- Product Code: 55546
CAS:
2370013-49-1
| Molecular Weight: | 584.08 g./mol | Molecular Formula: | C₂₉H₃₅ClFN₇O₃ |
|---|---|---|---|
| EC Number: | MDL Number: | ||
| Melting Point: | Boiling Point: | ||
| Density: | Storage Condition: | -20°C, protected from light |
Product Description:
DZD9008 is primarily used in the field of oncology as a targeted therapy for certain types of cancer. It functions as an inhibitor of specific mutations in the EGFR (epidermal growth factor receptor) gene, particularly those that are resistant to traditional treatments. This makes it a promising option for patients with non-small cell lung cancer (NSCLC) who have developed resistance to first-line EGFR inhibitors. By blocking the signaling pathways that promote cancer cell growth, DZD9008 helps to slow tumor progression and improve patient outcomes. Its application is currently under investigation in clinical trials to determine its efficacy and safety in treating advanced or metastatic cancers with specific genetic alterations.
Product Specification:
| Test | Specification |
|---|---|
| APPEARANCE | White to Off-white Solid |
| PURITY | 97.5-100 |
| Infrared spectrum | Conforms to Structure |
| NMR | Conforms to Structure |
Sizes / Availability / Pricing:
| Size (g) | Availability | Price | Quantity |
|---|---|---|---|
| 0.005 | 10-20 days | ฿7,992.00 |
+
-
|
| 0.025 | 10-20 days | ฿31,500.00 |
+
-
|
DZD9008
DZD9008 is primarily used in the field of oncology as a targeted therapy for certain types of cancer. It functions as an inhibitor of specific mutations in the EGFR (epidermal growth factor receptor) gene, particularly those that are resistant to traditional treatments. This makes it a promising option for patients with non-small cell lung cancer (NSCLC) who have developed resistance to first-line EGFR inhibitors. By blocking the signaling pathways that promote cancer cell growth, DZD9008 helps to slow tumor progression and improve patient outcomes. Its application is currently under investigation in clinical trials to determine its efficacy and safety in treating advanced or metastatic cancers with specific genetic alterations.
| Mechanism | - |
| Appearance | - |
| Longevity | - |
| Strength | - |
| Storage | - |
| Shelf Life | - |
| Allergen(s) | - |
| Dosage (Range) | - |
| Recommended Dosage | - |
| Dosage (Per Day) | - |
| Recommended Dosage (Per Day) | - |
| Mix Method | - |
| Heat Resistance | - |
| Stable in pH range | - |
| Solubility | - |
| Product Types | - |
| INCI | - |
Cart
No products
Subtotal:
฿0.00
฿0.00
Total :